• So Yun Lim, Yu Mi Jung, Yeonjae Kim, Gayeon Kim, Jaehyun Jeon, BumSik Chin, and Min-Kyung Kim.
• Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul, Korea.
• J. Korean Med. Sci. 2024 Mar 4; 39 (8): e100e100.

AbstractIn response to the Mpox domestic epidemic, South Korea initiated a nationwide vaccination program in May 2023, administering a 0.1 mL intradermal dose of JYNNEOS (Modified Vaccinia Ankara vaccine, Bavarian Nordic) to a high-risk group. To investigate the adverse reactions after intradermal JYNNEOS vaccination, an anonymous online survey was conducted at the National Medical Center from May 22 to July 31, 2023. Overall, 142 individuals responded. Over 80% of the respondents reported local reactions of predominantly mild severity. The predominant local reactions were pruritus, redness, and swelling; their incidence rates after the first dose were 66.2%, 48.1%, and 49.4%, respectively; the corresponding rates after the second dose were 69.2%, 60.6%, and 53.8%. Fewer respondents reported systemic symptoms. The most common systemic symptom was fatigue, the incidence rates of which after the first and second doses were 37.7% and 24.6%, respectively. Overall, the intradermally administered JYNNEOS vaccine appeared well tolerated.© 2024 The Korean Academy of Medical Sciences.

16 keywords...

hide…